Fc Engineering to target anti-tumour efficacy

Fc 工程瞄准抗肿瘤功效

• 批准号: 1674016
• 金额: --
• 依托单位: University of Southampton
• 依托单位国家: 英国
• 项目类别: Studentship
• 财政年份: 2015
• 资助国家: 英国
• 起止时间: 2015 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=studentship-1674016
• 关键词: Fc; Engineering; target; anti; tumour

The Biologics market and monoclonal antibodies (mAb) in particular represent the fastest growing sector of the pharmaceutical industry with global revenues of > £25 billion. Critical for their further development is a deeper understanding of their mode(s) of action coupled to improved technologies which will deliver ever safer and more efficacious agents. Our industrial partner, UCB is developing novel mAb-based medicines across a broad range of therapeutic areas including inflammatory and autoimmune diseases. UCB also has considerable expertise in antibody technologies including their engineering and expression. Key to their future development of the next generation of improved reagents is an understanding of how immune effector mechanisms such as complement and Fc receptors are engaged at the target cell surface in vivo. This project will employ novel technologies designed to more effectively target the immune effector responses to the desired target on cancer cells. It will involve the development and exploration of novel antibody platforms and technologies using molecular biology, protein engineering, cutting-edge immunoassays and in vivo models, ultimately facilitating the development of better treatments.The student will receive training in a variety of methodologies both at UCB and Southampton including molecular biology, antibody expression and purification, flow cytometry, tissue culture, in-vivo models and will benefit from academic and industrial supervision. Finally, this project will give a 'real life' experience outside academia and create a better appreciation of the translational and commercial value of research.

生物制品市场和单克隆抗体（mAb）是制药行业增长最快的领域，全球收入超过250亿英镑。对它们的进一步发展至关重要的是更深入地了解它们的作用模式，再加上改进的技术，这些技术将提供更安全和更有效的药剂。我们的工业合作伙伴UCB正在广泛的治疗领域开发基于mAb的新型药物，包括炎症和自身免疫性疾病。UCB在抗体技术方面也有相当多的专业知识，包括它们的工程和表达。他们未来开发下一代改进试剂的关键是了解免疫效应机制，如补体和Fc受体如何参与体内靶细胞表面。该项目将采用新技术，旨在更有效地将免疫效应反应靶向癌细胞上的所需靶点。学生将在UCB和南安普顿接受各种方法学的培训，包括分子生物学，抗体表达和纯化，流式细胞术，组织培养，免疫分析，免疫组织化学，免疫细胞化学体内模型，并将受益于学术和工业监督。最后，这个项目将给学术界以外的"真实的生活"体验，并创造一个更好的翻译和商业价值的研究升值。